This dashboard provides a comprehensive statistical overview of pharmaceutical and biotech companies actively developing treatments for neurodegenerative diseases in NeuroWiki. It serves as a central hub for understanding the therapeutic landscape, company capabilities, and development pipelines.
| Metric | Value |
|---|---|
| Total Company Pages | 198[1] |
| Companies with AD Programs | 87[1:1] |
| Companies with PD Programs | 72[1:2] |
| Companies with ALS Programs | 45[1:3] |
| Companies with FTD Programs | 28[1:4] |
| Clinical-Stage Companies | 94 |
| Preclinical/Discovery | 104 |
The largest therapeutic area in neurodegeneration, with 87 companies developing treatments targeting amyloid-beta, tau, neuroinflammation, and other mechanisms.
Key Companies:
72 companies focusing on alpha-synuclein, LRRK2, GBA1, and mitochondrial dysfunction.
Key Companies:
45 companies targeting SOD1, C9orf72, TDP-43, and neuroprotection mechanisms.
Key Companies:
28 companies developing treatments for tau, TDP-43, and progranulin.
| Stage | Companies |
|---|---|
| Phase 3 | 12 |
| Phase 2 | 28 |
| Phase 1 | 31 |
| Preclinical | 67 |
| Discovery | 52 |
Companies leveraging monoclonal antibodies for target engagement.
Companies using AAV vectors, ASOs, and RNAi for genetic interventions.
Traditional pharmaceutical approaches targeting enzymes and receptors.
Companies developing stem cell or cellular replacement approaches.
Based on mechanism novelty, target diversity, and delivery approaches.
| Drug | Company | Mechanism | Indication |
|---|---|---|---|
| Leqembi | Biogen/Eisai | Anti-Aβ antibody | AD |
| Kisunla | Eli Lilly | Anti-Aβ antibody | AD |
| BIIB122 | Biogen | LRRK2 inhibitor | PD |
| Trontinemab | Roche | Brain-penetrant anti-Aβ | AD |
Last updated: 2026-03-17